Tempus AI, Inc. (NASDAQ: TEM) is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, with a strong focus on oncology and health information services. The Tempus news stream highlights how the company’s platform, genomic testing capabilities, and data-driven tools are used in collaborations, research, and commercial partnerships.
Readers can follow announcements about Tempus’s strategic collaborations with leading health systems and academic medical centers, such as multi-year precision oncology initiatives and efforts to expand access to genomic testing for cancer patients. News items also cover research partnerships with nonprofit foundations, including multi-omic studies designed to build comprehensive datasets for specific diseases like follicular lymphoma.
Tempus frequently reports on its participation in major scientific conferences, where it presents abstracts based on its de-identified multimodal database and tools like Tempus Lens. These updates include studies on tumor genomics, immune microenvironments, biomarkers, and real-world outcomes across a range of cancers, including gastrointestinal, breast, and other solid tumors. In addition, the news feed features corporate and financial updates, such as preliminary revenue results, contract value milestones, and appearances at investor conferences.
By reviewing the latest TEM news, investors and healthcare professionals can see how Tempus’s AI-enabled precision medicine solutions are being applied in clinical settings, research collaborations, and life sciences partnerships. This page is a resource for tracking ongoing developments in Tempus’s diagnostics, data and applications businesses, as well as its role in advancing data-driven approaches to cancer care and therapeutic development.
Tempus AI (NASDAQ: TEM) released preliminary, unaudited results for Q4 and full year 2024. The company reported approximate full-year revenue of $693 million, showing ~30% year-over-year growth, and Q4 revenue of $200 million, representing ~35% year-over-year growth.
The company's genomics revenue is expected to grow ~30% in Q4, while data and services revenue is projected to grow ~45%. Tempus expects to achieve ~99% of its 2024 revenue guidance and ~100% of adjusted EBITDA guidance, despite noting some softness in CRO revenues. Both Q4 and full-year results showed continued improvement in adjusted EBITDA compared to previous periods.
These preliminary results are subject to change pending completion of year-end close and review procedures. Final detailed financial results will be reported during the company's first earnings call of 2025.
Tempus (NASDAQ: TEM) announced a multi-year collaboration with Genialis to develop RNA-based biomarker algorithms for cancer treatment. Genialis will utilize Tempus' multimodal dataset to validate and enhance their AI foundation model, which uses data from approximately 1 million RNA-sequencing samples.
Through this partnership, Genialis gains access to Tempus' analytics platform, Lens, providing development tools and de-identified patient records. In return, Tempus receives rights to evaluate and potentially license Genialis-developed algorithms for commercialization within their xR platform.
The collaboration has already contributed to the launch of Genialis™krasID, the first commercial algorithm predicting patient response to KRAS-targeted therapies across cancer types. This algorithm, validated using Tempus' real-world data, effectively stratifies patients into response likelihood groups.
Tempus AI (NASDAQ: TEM) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 13-16, 2025, in San Francisco. The company's involvement includes two key events:
1. A presentation and Q&A session with investors led by Founder and CEO Eric Lefkofsky on Monday, January 13
2. A panel discussion on Policy Outlook for Artificial Intelligence in Healthcare & Diagnostics featuring Chief Scientific Officer Kate Sasser on Wednesday, January 15
The company will provide a live webcast option for accessing the January 13 presentation. Tempus AI specializes in leveraging artificial intelligence to enhance precision medicine and improve patient care outcomes.
Tempus has secured in-network provider status with several major healthcare insurers, including Blue Cross Blue Shield (BCBS) of Illinois, Blue Shield of California, and Avalon Healthcare Solutions. Through the Avalon agreement, Tempus becomes a participating provider with BCBS entities in North Carolina, South Carolina, Vermont, as well as Capital BlueCross and CareSource in four markets. This expansion enhances Tempus' presence with commercial health plans in the East.
The agreements enable patients with these insurance plans to access Tempus' comprehensive molecular profiling portfolio as a participating provider, potentially leading to lower out-of-pocket costs for testing services. These molecular profiling tests help physicians make more informed, personalized treatment decisions throughout patients' care journeys.
Tempus AI (NASDAQ: TEM) announces a significant Medicare coverage decision for its ECG-AF device. The Centers for Medicare and Medicaid Services (CMS) will provide reimbursement for cardiac dysfunction assessments using the Tempus ECG-AF algorithm, with a Medicare rate of $128.90 effective January 1, 2025.
The FDA-cleared device analyzes 12-lead ECG recordings to detect signs of atrial fibrillation (AF) risk within 12 months for patients 65 and older. This development follows Tempus' earlier FDA 510(k) clearance, marking the first AF indication in cardiovascular machine learning-based notification software. With nearly one million Americans having undetected AF and over 100 million ECGs performed annually in the U.S., this AI-powered solution aims to enhance early disease detection.
Personalis (Nasdaq: PSNL) and Tempus AI (Nasdaq: TEM) have expanded their commercial relationship to benefit the biopharma industry. Originally agreed upon in November 2023, the collaboration aims to bring ultra-sensitive MRD testing to market. The partnership was launched at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, with Tempus serving as the exclusive commercial diagnostic partner for Personalis' NeXT Personal® Dx. This product is designed for broad patient adoption in breast and lung cancers and immunotherapy monitoring across all solid tumors.
Following a positive market reaction, Tempus will now offer Personalis' NeXT Personal MRD product to pharmaceutical and biotech customers. These customers can bundle MRD testing with other Tempus offerings within a given study. Chris Hall, CEO of Personalis, believes that this expansion will accelerate market penetration and capitalize on new opportunities.
Tempus AI (NASDAQ: TEM), a leader in AI-driven precision medicine and healthcare technology, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The event will take place in New York on December 3, 2024. Tempus Founder and CEO Eric Lefkofsky is scheduled to engage in a fireside discussion at 3:00 p.m. ET during the conference.
Tempus announced a collaboration with Flatiron Health to integrate its genomic testing capabilities into Flatiron's OncoEMR® platform through Molecular Profiling Integration (MPI). This integration will provide 4,200 providers across 800 community-based cancer care locations with direct access to Tempus' suite of testing options within their workflow. The system enables electronic ordering, tracking, and result delivery through a unified ordering system, reducing administrative burden. The integration includes access to various Tempus tests including xT, xR, xF/xF+, xG/xG+ Ambry, and xM/xM, along with AI-enabled algorithmic add-on tests.
Tempus has published a study in JAMA Network Open demonstrating the advantages of combining RNA and DNA sequencing in advanced non-small cell lung cancer (NSCLC) treatment. The retrospective study of over 5,500 NSCLC patients revealed that concurrent RNA- and DNA-based next-generation sequencing detected more actionable structural variants than DNA sequencing alone. 8.8% of patients showed at least one actionable variant, with the combined approach increasing variant detection by 15.3% and more than doubling the identification of rare structural variants compared to DNA sequencing alone.
Tempus AI (NASDAQ: TEM) announced nine abstracts accepted for presentation at the Society for Immunotherapy of Cancer's 39th Annual Meeting in November 2024. Key highlights include two poster presentations: one validating a novel multi-omic algorithm for predicting immune checkpoint inhibitor (ICI) treatment outcomes using the Immune Profile Score (IPS), and another analyzing the cost-effectiveness of molecular biomarkers combined with CT imaging for treatment response monitoring. The second study, involving 4,147 cancer patients, demonstrated significant cost savings when using molecular biomarkers alongside CT imaging, particularly in small cell lung cancer treated with ICI-chemotherapy.